Live Panel Schedule for Digital RESI September 2020

3 Sep

By Joey Wong, Investor Research Analyst, LSN

With only one week left, Digital RESI September 2020 is right around the corner! We are very excited to announce the live panel schedule for the conference.

All panels at Digital RESI September will be live-streamed. There will be two live panel sessions each day, starting as early as next week and will continue through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

It is worth noting that Global Investment and Partnership Panel, sponsored by Onelin Capital, is open to the public (no RESI registration required). Interested readers are welcome to RSVP here and participate in this panel.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more. If you haven’t already, register here for RESI September 2020 to participate in these live panels!

Below is the schedule for next week’s live panel sessions:

 

Corporate VC Panel – “The Corporate Landscape Morphed & New Opportunities Abound”

Date & Time: Tuesday, September 8, 10:00 – 10:50 am EST

  • Andy Merken (Moderator), Partner and Co-Chair, Life Sciences, Burns & Levinson
  • Lana Ghanem, Managing Director, Hikma Ventures
  • Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund
  • Tom Gibbs, Director, Debiopharm Innovation Fund

Medtech Strategics Panel – “Large Medical Device Firms Seeking External Innovation”

Date & Time: Tuesday, September 8, 12:00 – 12:50 pm EST

  • Geoff Dacosta (Moderator), Director of Business Development and Licensing, Medtronic
  • Christina Salys, Director of New Business development, Intuitive Surgical
  • David Uffer, Senior Partner, Alira Ventures
  • Rupert Winckler, Head of EMEA New Business Development, Olympus Corporation

Health System Partners Panel – “Care Providers and Payers Seek New Technologies”

Date & Time: Wednesday, September 9, 12:00 – 12:50 pm EST

  • Cyrll Philip, Principal, Providence Ventures
  • Linda Maxwell, Director, Biomedical Zone
  • Mayank Taneja, Director of Venture Investments, OSF Healthcare Ventures
  • Rajesh Aggarwal, Executive Vice President, Jefferson Strategic Ventures

Seed Funds Panel – “Investing in Emerging Science to Pursue High Rewards”

Date & Time: Wednesday, September 9, 2:00 – 2:50 pm EST

  • Gary Gershony (Moderator), Life Science Angels
  • Anya Roy, Head of Illumina Accelerator Cambridge, Illumina Accelerator
  • Jun Deng, Investment Partner, Joyance Partners
  • Nancy Kaufman, CEO, Beacon Capital
  • Prathna Ramesh, Executive Director, Maple Leaf Angels

Oncology Innovation Panel – “The Search for New Approaches to Diagnosing & Treating Cancer”

Date & Time: Thursday, September 10, 12:00 – 12:50 pm EST

  • Steve Yoder (Moderator), Vice President of Business Development, Taiho Oncology
  • Anthony Bajoras, Managing Director, Cancer Fund
  • Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy
  • Duncan Young, Director of Search and Evaluation Oncology, Business Development & Licensing, AstraZeneca
  • Mark Krul, Partner, Aglala Oncology Fund

Global Investment and Partnership Panel – “Asia Firms Looking to Build Global Partnerships”

Date & Time: Thursday, September 10, 8:00 – 8:50 pm EST (Sponsored by Onelin Capital, Open to the public)

  • Judy Lee (Moderator), General Manager, Onelin Capital
  • Haolin Sung, Managing Partner, Chaperone Investment
  • Haruhiko Sugino, Director of Global Business Development, Otsuka Pharmaceuticals
  • Weiyong Sun, Senior Director of Specialty Medicine Search & Evaluation, Daichi Sankyo
  • Yao Li Ho, Senior Director of Business Development, LYFE Capital

Impact Investors Panel – “Life Science Investors Looking for More Than Financial Returns”

Date & Time: Friday, September 11, 12:00 – 12:50 pm EST

  • Lore Gruenbaum (Moderator), Vice President of Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Chris Penland, Vice President of BioPharma Programs, Cystic Fibrosis Foundation
  • Kuldip Dave, Vice President of Research, ALS Association
  • Michael Cole, Founder and General Partner, Global Neurohealth Ventures
  • Paul Larkin, Manager of Research Innovation, Crohn’s and Colitis Foundation

Hot Investor Mandate: Korea-Based VC Invests in Oncology & Autoimmune Disease Therapeutics, Seeks Companies Interested in Korean Market

3 Sep

A venture capital firm based in South Korea, affiliated with a leading pharmaceutical company, generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

In regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Conglomerate Seeks In-Licensing and Investment Opportunities in Medical Devices, Including Single-Use Devices, Orthopedic Materials, and More

3 Sep

A large conglomerate headquartered in China’s primary business is in single-use medical devices with a wide range of product lines in consumables, orthopedic materials, and blood purification. The group also have subsidiaries in biopharmaceutical, healthcare services, finance, and real estate. As a leading provider of healthcare system solutions, the firm is actively expanding its healthcare business in China. The group is seeking product-based collaboration opportunities with early stage medical device businesses overseas, primarily through joint venture or incubation. The firm’s newly opened incubator serves as a one-stop shop for early stage medical device companies by providing capital, R&D services, clinical trial services, CFDA registration, and distribution channels. Typical investments range from RMB 1-30 million (US$0.1 – 4.4 M), while there is no set upper limit. The firm would also consider in-licensing opportunities.

The firm is focusing on medical devices with an elevated interest in coronary stent, vascular ultrasound, endoscope, and surgical devices. The firm is also interested in medical technologies that are complimentary to its product line, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The group prefers products that have received FDA clearance/approval or at early commercial stage, while it is also open to projects that are pending an FDA decision. The group would also consider biopharmaceutical assets in kidney diseases.

The firm is seeking strong management teams with mature products that have received or are close to receiving regulatory approval. The firm is interested in forming joint venture or attracting overseas companies to its incubator.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office Invests in Medical Device & Diagnostics Companies with Large Market Potential, with Preference for Canada-Based Companies

3 Sep

A famiily office located in Canada looks to invest in clinical stage medical devices and diagnostics technologies as well as digital health companies. The firm looks to invest in companies with large market opportunities. The firm prefers to invest in Canadian companies, but will consider companies outside of Canada if they wish to expand to the Canadian market. The firm prefers to co-invest alongside other investors, and will invest $100,000-$250,000 in the initial investment, potentially contributing to additional rounds of funding.

The firm is looking for device companies, either in the medical device or diagnostic space. The firm will also consider digital health companies, focusing on mobile applications. For devices and diagnostics, the firm prefers 510k devices, but will consider PMA devices as well. These devices should be in the clinical development phase. The firm is indication agnostic, but does look for there to be a large market potential.

The firm looks for companies with strong management teams with good team dynamics, although previous entrepreneurial experience is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border VC with USA & Asian Offices Invests in Therapeutics & Digital Health Technologies with Novel, Differentiated Strategies

3 Sep

A healthcare-focused venture capital firm invests in companies and people that are changing the way people treat human health through new approaches and technologies. The firm invests in early-stage technologies to build the next-generation companies. The firm partners with companies early on as the firm looks to support visionary teams, cutting-edge healthcare technologies and those at the forefront of medicine. The firm’s teams are based in Boston and Taiwan.

For early-stage therapeutics, the firm focuses on novel approaches that achieve differentiated therapeutic results, regardless of modalities. The firm will engage with pre-clinical developments where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages. Key areas of interest include, immunological diseases, neurological diseases, metabolic diseases, and infectious diseases.

For digital health technologies, the firm looks for technology platforms that enable pertinent scientific insights into drug development and design or novel approaches to enhance delivery of care from providers to patients. Key areas of interest include, synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Invests Up to €10M Across Broad Life Science & Healthcare Sectors

3 Sep

A firm based in Western Europe focuses on investment opportunities in Europe but is open to considering investments in China as well. Initial equity-investments range in size from € 1 million up to € 10 million.

The firm invests broadly within the healthcare sector, and manages funds in Health-tech, Sustainable Chemistry, Digital Growth (with a focus on digital health and Industry 4.0).

The firm’s funds invest in companies that are in revenue stage or pre-revenue stage provided that the technologies and products are disruptive and have the potential to significantly address global markets.

The firm looks for exceptional management teams but is ready to support its portfolio companies in building their organization and being a sparring partner for strategy and business development discussions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Vehicle of Angel Group Seeks Early-Stage Companies Across All Life Science Sectors and Assists China Market Entry

3 Sep

The main investment and operation vehicle of an angel group was formed on the basis of investing in passionate early-stage entrepreneurs developing novel technologies. The firm’s areas of interest include AI, big data, pharmaceuticals, healthcare, wearable devices, etc. The firm has invested in academic spin-offs from Harvard and MIT as well.

The firm has three sub-entities that work closely together in order to find valuable US high-tech startups, conduct rigorous screening, help them with accelerated growth and expand into the Chinese market, as well as providing exit strategy guidance.

The firm is interested in a wide range of life science areas. The firm will look at Therapeutics, Medical Devices, Digital Health, and Diagnostics. The firm seeks to invest in early-stage companies, within therapeutics, the firm will look at stages before phase I.

The firm has no specific company or team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →